...
search icon
oric-img

Oric Pharmaceuticals Inc Share Price

ORIC
NSQ
$9.99
-$0.25
(-2.44%)
1D
Industry: Biotechnology Sector: Health Care

Oric Pharmaceuticals Inc Analyst Forecast

Oric Pharmaceuticals Inc Share Price Chart

Oric Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$997.27M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
702.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.33
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.9 L
$14.93 H
$9.99

About Oric Pharmaceuticals Inc, Common Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Oric Pharmaceuticals Inc Stock Returns

Time FrameORICSectorS&P500
1-Week Return-4.13%-1.08%-1.38%
1-Month Return-1.48%-0.47%-1.81%
3-Month Return-18.05%2.13%1.38%
6-Month Return1.63%17.04%5.68%
1-Year Return20.8%6.56%11.74%
3-Year Return106.4%16.78%65.15%
5-Year Return-69.44%34.34%73.68%
10-Year Return-61.23%137.88%260.03%

Oric Pharmaceuticals Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue970.00K897.00K966.00K1.03M1.11M[{"date":"2020-12-31","value":87.62,"profit":true},{"date":"2021-12-31","value":81.03,"profit":true},{"date":"2022-12-31","value":87.26,"profit":true},{"date":"2023-12-31","value":93.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(970.00K)(897.00K)(966.00K)(1.03M)(1.11M)[{"date":"2020-12-31","value":-97000000,"profit":false},{"date":"2021-12-31","value":-89700000,"profit":false},{"date":"2022-12-31","value":-96600000,"profit":false},{"date":"2023-12-31","value":-103200000,"profit":false},{"date":"2024-12-31","value":-110700000,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses74.19M78.87M91.77M109.75M141.79M[{"date":"2020-12-31","value":52.32,"profit":true},{"date":"2021-12-31","value":55.63,"profit":true},{"date":"2022-12-31","value":64.72,"profit":true},{"date":"2023-12-31","value":77.4,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(74.19M)(78.87M)(91.77M)(110.78M)(142.90M)[{"date":"2020-12-31","value":-7418600000,"profit":false},{"date":"2021-12-31","value":-7887100000,"profit":false},{"date":"2022-12-31","value":-9176700000,"profit":false},{"date":"2023-12-31","value":-11078000000,"profit":false},{"date":"2024-12-31","value":-14289500000,"profit":false}]
Total Non-Operating Income/Expense789.00K297.00K5.29M--[{"date":"2020-12-31","value":14.91,"profit":true},{"date":"2021-12-31","value":5.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(73.70M)(78.72M)(89.12M)(100.70M)(127.85M)[{"date":"2020-12-31","value":-7370300000,"profit":false},{"date":"2021-12-31","value":-7871500000,"profit":false},{"date":"2022-12-31","value":-8912200000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false},{"date":"2024-12-31","value":-12784700000,"profit":false}]
Income Taxes23.57M(1.04M)2.35M--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-4.4,"profit":false},{"date":"2022-12-31","value":9.99,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(97.27M)(77.68M)(91.48M)--[{"date":"2020-12-31","value":-9727000000,"profit":false},{"date":"2021-12-31","value":-7767700000,"profit":false},{"date":"2022-12-31","value":-9147700000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(73.70M)(78.72M)(89.12M)(100.70M)(127.85M)[{"date":"2020-12-31","value":-7370300000,"profit":false},{"date":"2021-12-31","value":-7871500000,"profit":false},{"date":"2022-12-31","value":-8912200000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false},{"date":"2024-12-31","value":-12784700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(73.70M)(77.68M)(89.12M)(100.70M)(127.85M)[{"date":"2020-12-31","value":-7370300000,"profit":false},{"date":"2021-12-31","value":-7767700000,"profit":false},{"date":"2022-12-31","value":-8912200000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false},{"date":"2024-12-31","value":-12784700000,"profit":false}]
EPS (Diluted)(6.22)(2.07)(2.25)(1.96)(1.82)[{"date":"2020-12-31","value":-622,"profit":false},{"date":"2021-12-31","value":-207,"profit":false},{"date":"2022-12-31","value":-225,"profit":false},{"date":"2023-12-31","value":-196,"profit":false},{"date":"2024-12-31","value":-182,"profit":false}]

Oric Pharmaceuticals Inc Ratios

Oric Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

ORIC
Cash Ratio 14.23
Current Ratio 14.65

Oric Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ORIC
ROA (LTM) -25.23%
ROE (LTM) -39.73%

Oric Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ORIC
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Oric Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ORIC
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.44
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.13

FAQs

What is Oric Pharmaceuticals Inc share price today?

Oric Pharmaceuticals Inc (ORIC) share price today is $9.99

Can Indians buy Oric Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Oric Pharmaceuticals Inc (ORIC) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ORIC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Oric Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Oric Pharmaceuticals Inc (ORIC) via the Vested app. You can start investing in Oric Pharmaceuticals Inc (ORIC) with a minimum investment of $1.

How to invest in Oric Pharmaceuticals Inc shares from India?

You can invest in shares of Oric Pharmaceuticals Inc (ORIC) via Vested in three simple steps:

  • Click on Sign Up or Invest in ORIC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Oric Pharmaceuticals Inc shares
What is Oric Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Oric Pharmaceuticals Inc (ORIC) is $14.93. The 52-week low price of Oric Pharmaceuticals Inc (ORIC) is $3.9.

What is Oric Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Oric Pharmaceuticals Inc (ORIC) is

What is Oric Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Oric Pharmaceuticals Inc (ORIC) is 2.44

What is Oric Pharmaceuticals Inc dividend yield?

The dividend yield of Oric Pharmaceuticals Inc (ORIC) is 0.00%

What is the Market Cap of Oric Pharmaceuticals Inc?

The market capitalization of Oric Pharmaceuticals Inc (ORIC) is $997.27M

What is Oric Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Oric Pharmaceuticals Inc is ORIC

How Can Investors Use Oric Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Oric Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Oric Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Oric Pharmaceuticals Inc shares for Indian investors?

When investing in Oric Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Oric Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Oric Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Oric Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Oric Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top